Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial
RCT (n=1007) found testosterone treatment for 2 years reduced proportion of participants with type 2 diabetes beyond effects of lifestyle programme (2-h glucose ≥11.1 mmol/L oral glucose tolerance test in 21% placebo and 12% testosterone group; RR 0.59, 95% CI 0.43-0.80;p=0.0007)
Source:
The Lancet Diabetes & Endocrinology
Resource links:
SPS commentary:
The researchers note that increases in haematocrit might be treatment limiting. A commentary discusses if these findings can influence clinical practice and warns that uncertainty with respect to long-term cardiovascular risks means testosterone cannot currently be recommended for preventing diabetes.